In this article
Singapore biotechnology company Lion TCR Pte. Ltd. was approved by the Singapore Health Sciences Authority (HSA), and its candidate product LioCyxâ„¢ can be used for Phase I/II clinical research for the treatment of liver cancer that recurs after transplantation. This type of trial was approved for the first time in Singapore. It uses precision T cell receptor (TCR) immune cell therapy to target hepatitis B virus (HBV)-related liver cancer. At least 80% of liver cancers in Asia are caused by HBV, and 80% of the 800,000 new liver cancer cases in the world are diagnosed in the Asia-Pacific region, covering China, Vietnam, Thailand, Indonesia, South Korea, and Singapore. Liver cancer is the third deadliest cancer in the world, with very limited treatment options and poor treatment results. At present, there is no effective treatment for patients with liver cancer recurrence after liver transplantation.
LioCyxâ„¢ was developed by Professor Antonio Bertoletti, the scientific founder of Lion TCR and a world-renowned HBV liver cancer clinical scientist. In Singapore and China, some LioCyxâ„¢ trials sponsored by researchers have shown good safety and encouraging efficacy. Dr. Victor Li Lietao, founder and CEO of Lion TCR, said: "We are very pleased that the Phase I/II clinical trial of LioCyxâ„¢ has been approved. LioCyxâ„¢ is Singapore's first TCR-T cell therapy for liver cancer. HSA Singapore has been reviewing our innovative immunotherapy clinical trial applications very efficiently, transparently and professionally."
Recruitment of patients for Phase I/II clinical trials will begin at the National University of Singapore Hospital (NUH), with Lion TCR planning to include both Singapore and China medical centers in the trial — marking a significant step forward in the global effort to develop effective immunotherapy options for one of the world's most deadly cancers.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Sai Sree
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.